| # | Drug | Count |
|---|---|---|
| 0 | TEMOZOLOMIDE | 12 |
| 1 | CISPLATIN | 5 |
| 2 | BEVACIZUMAB | 4 |
| 3 | DOXORUBICIN | 4 |
| 4 | ETOPOSIDE | 4 |
| 5 | CAPECITABINE | 3 |
| 6 | DOXORUBICIN HYDROCHLORIDE | 2 |
| 7 | OXALIPLATIN | 2 |
| 8 | PEMBROLIZUMAB | 2 |
| 9 | CARBOPLATIN | 1 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | MOSUNETUZUMAB | 1 | 0.0009 |
| 1 | ETOPOSIDE PHOSPHATE | 1 | 0.0006 |
| 2 | TEMOZOLOMIDE | 12 | 0.0006 |
| 3 | DOSTARLIMAB | 1 | 0.0004 |
| 4 | CISPLATIN | 5 | 0.0001 |
| 5 | PANITUMUMAB | 1 | 0.0001 |
| 6 | DOXORUBICIN HYDROCHLORIDE | 2 | 0.0001 |
| 7 | OBINUTUZUMAB | 1 | 0.0001 |
| 8 | EVEROLIMUS TABLETS | 1 | 0.0001 |
| 9 | ETOPOSIDE | 4 | 0.0001 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Alkylating Drug [EPC] | 13 | 0.0001 |
| 1 | Topoisomerase Inhibitor [EPC] | 4 | 0.0001 |
| 2 | Programmed Death Ligand-1 Blocker [EPC] | 1 | 0.0000 |
| 3 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 4 | 0.0000 |
| 4 | Platinum-based Drug [EPC] | 8 | 0.0000 |
| 5 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 4 | 0.0000 |
| 6 | Epidermal Growth Factor Receptor Antagonist [EPC] | 1 | 0.0000 |
| 7 | Nucleoside Metabolic Inhibitor [EPC] | 4 | 0.0000 |
| 8 | CD20-directed Cytolytic Antibody [EPC] | 1 | 0.0000 |
| 9 | Kinase Inhibitor [EPC] | 1 | 0.0000 |